spacer
home > ebr > Autumn 2011
PUBLICATIONS

European Biopharmaceutical Review

ebr
Autumn 2011
   
Text
PDF
BioBusiness, Finance & Communication

Prepared to Launch

Mike Rea at IDEA Pharma considers the importance of product lifecycle decisions and explains how assessing commercial and regulatory risk, in addition to considerations of investment and time-to-market, can lead to a strong competitive advantage.

 
view
download pdf

App Potential

As the internet promotes customer satisfaction by encouraging feedback via online publications, the importance of maintaining a web presence is growing. Kelly Sladek at SCORR Marketing outlines the inevitable evolution of online promotions.

 
view
download pdf

Digital Exchange

A recent survey demonstrates an increasing dependence on electronic communication media within the biotech sector. Linda Bowers at IntraLinks evaluates the implementation of web-based document exchange solutions.

 
view
download pdf
bullet
BioFinance and Management

Trimming the Fat

Lean Six Sigma has been proven to be an effective and helpful tool for contract laboratories providing biopharmaceutical analysis. Melanie Dippel at Charles River Biopharmaceutical Services GmbH looks at benefi cial collaborations with an outsourcing partner.

 
view
download pdf
bullet
BioBusiness Development

The Biotechisation of Pharma

With the noticeable rise of ‘biotechisation’ in pharma companies in recent years, Flavia Botschen and Markus Thunecke at Catenion look at how this will affect all related branches of the densely interwoven biopharmaceutical industry.


 
view
download pdf
bullet
Discovery Technology

Protein Production

Igor A Kaltashov at the University of Massachusetts-Amherst assesses the advantages and challenges of mass spectrometry-based methods used for characterising protein as well as its broader impact on the production process.

 
view
download pdf
BioDiscovery

Flow Cytometry Outsourcing

Carla G Hill and Thomas W McCloskey at ICON Central Laboratories report on how the use of flow cytometry for clinical trial testing is set to increase, as accurate evaluation of cell-based biomarker assays becomes a necessity in the assessment of biologic drug candidates.

 
view
download pdf
BioDevelopment

Cause and Effect

Biomarkers are integral to improved diagnostics and novel therapeutics. Ioannis Amarantos, Thomas Laufer and Thomas Brefort at febit biomed GmbH study their four primary categories of application and discuss research case studies of miRNA development.

 
view
download pdf
bullet
Legal, Regulatory and Public Policy

Regulatory Challenges

The Survey Says

Alan Trounson and Elona Baum at the California Institute for Regenerative Medicine (CIRM) run through their research on current perspectives regarding regulatory uncertainty when facing challenges for commercialisation in the fi eld of regenerative medicine.

 
view
download pdf
bullet
Biodevelopment and Manufacturing

Single-Use Technology

At Your Disposal

Nicole O’Brien at Gallus BioPharmaceuticals discovers that the road to a fully disposable biomanufacturing process – from bench to commercial production – is just on the horizon, and offers an insight into how it is transforming biotherapeutics.

 
view
download pdf
bullet
BioFormulation and Manufacturing

Peptide Synthesis

Building Bonds

In-depth knowledge of peptide production methods to optimise yield and purity is critical to faster and more cost-effective commercialisation of peptidebased therapies, elaborates Gary Hu at the American Peptide Company.

 
view
download pdf
BioManufacturing

Drawn to Scale

Successful manufacturing of biopharmaceuticals relies on good process design, scale up and control strategies. Graham McCreath and Mahesh Shivhare at Fujifilm Diosynth Biotechnologies demonstrate the possibilities that small scale fermentation can offer.


 
view
download pdf
bullet
CANCER FOCUS

Setting Your Sites

While there are numerous challenges for the effective contact research management of most clinical trials, oncology studies pose even further complications. Erin Anderson and Daryl Ann Fallon of Premier Research Group Limited focus on the goals and objectives the biotechnology sector face today.

 
view
download pdf

Peptide Potential

Citing recent research into the potential of a synthetic peptide known as ‘p28’, Tapas K Das Gupta, David R Volk and Craig W Beattie at CDG Therapeutics, Inc relate how new findings on this peptide could alter future cancer therapies.

 
view
download pdf
bullet
APPLIED RESEARCH, DEVELOPMENT AND PRODUCTION

Express Delivery

siRNAs have proved their capacity to perform in a wide range of applications, from human diseases to plant pathogen resistance. Kathleen Hefferon at the University of Toronto explains how their development has been adapted within the medicinal and agricultural fi elds.

 
view
download pdf
bullet
REGIONAL UPDATES

The Future’s Orange

Annemiek Verkamman at Life Sciences Health looks at the social, technological and sector trends within the Dutch life sciences industry as these companies compete to be global players.


 
view
download pdf
 
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October

News and Press Releases

ASPIRE International Conference 2018: Pre-registration now open!

The ASPIRE international conference is taking place on the 28th February and 1st March 2018 at the Vox Conference Centre in Birmingham. The conference brings together members of the research community including research professionals from the NHS, Clinical Trial Networks and international organisations. The ASPIRE conference will allow delegates to share knowledge and best practise with the focus on enhancing the efficiency and productivity of clinical research across the UK and beyond.
More info >>

White Papers

Orthogonal Approaches for the Analysis of Protein Sequence

Ludger Ltd

One of the most important classes of biopharmaceuticals is monoclonal antibodies. They are expressed from living cells, and are consequently subject to complex biochemical pathways. Not all of these routes are fully understood, and many are sensitive to the subtlest of environmental changes. Changes such as these can affect the final biopharmaceutical sequence, structure and post-translational modifications, not to mention any changes that may occur during further purification. This often means that the final product from one batch may be different from the last in another batch. Each batch is a complicated mix of similar molecules, and analysis of the degree of batch-to-batch variation is therefore very important to the establishment of the drug's safety for medicinal use and patient administration.
More info >>

Industry Events

BIO-Europe® 2017

6-8 November 2017, Messedamm 26 14055 Berlin Germany

The 23rd annual BIO-Europe® event is the largest biotechnology partnering conference held in Europe. Over 3,800 global decision makers from biotechnology, pharma and finance annually attend BIO-Europe to identify new business opportunities and develop strategic relationships. Business development executives and dealmakers consider BIO-Europe a must-attend event and an effective business strategy enabling them to meet and present to numerous potential partners. BIO-Europe features the industry’s most advanced web-based partnering system enabling delegates from all parts of the biotechnology value chain to quickly identify, engage and enter into strategic relationships that drive their business successfully forward. BIO-Europe's world-class workshops, panels and active exhibition along with thousands of prescheduled one-to-one meetings make this event an unrivaled forum for companies across the biotech value chain to meet and do business.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement